Menactra Vaccine
Regulated Product — Business License RequiredB2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.
Product Overview
Menactra Vaccine is a meningococcal conjugate vaccine. Its labelling describes it for active immunisation to help prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135, and it is described for individuals from 9 months through 55 years of age.
Product Information
The following description reflects information associated with the meningococcal A, C, Y and W-135 conjugate vaccine and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.
Described Uses
- Described for active immunisation to help prevent invasive meningococcal disease caused by N. meningitidis serogroups A, C, Y and W-135, in individuals from 9 months through 55 years of age
- Commonly described for routine use in adolescents (around 11–12 years) with a booster at about 16 years
- Described as relevant for people at increased risk — for example those in shared-living settings such as dormitories, or with conditions such as asplenia, complement component deficiencies, or HIV infection
Described Dosage & Administration
- Administered only by a healthcare professional as an intramuscular injection — not self-administered
- All doses in the schedule set by the healthcare provider should be completed for the vaccine to work as intended
- A single booster dose is described for people aged 15 to 55 years at continued risk, particularly if 4 to 5 years have passed since a previous dose
- Described as not to be given intravenously, subcutaneously, or intradermally
Described Side Effects
Commonly described side effects include:
- Injection-site reactions (pain, redness, swelling)
- Irritability
- Loss of appetite and drowsiness
- Nausea, vomiting or diarrhoea
- Headache and tiredness
These are described as usually short-lived. A doctor should be informed if they do not go away, and any severe, persistent, or unexpected reaction requires prompt medical attention.
Precautions
- Any health conditions or diseases should be disclosed to the doctor before the vaccine is given
- All current medication should be disclosed to the doctor
- Any previous allergic reaction to a vaccine or vaccine component should be disclosed before administration
- Pregnant women and breastfeeding mothers should consult their doctor before receiving the vaccine
This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.
B2B, Import & Export Enquiries
SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.
We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.
Request Product Information
Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.
Frequently Asked Questions
Per its labelling it is a meningococcal conjugate vaccine given for active immunisation to help prevent invasive meningococcal disease caused by N. meningitidis serogroups A, C, Y and W-135, in individuals from 9 months through 55 years of age. SDO Pharma has not independently verified the manufacturer’s claims and does not claim any specific regulatory approval unless independently confirmed.
Its labelling states it is administered by a healthcare professional as an intramuscular injection and is not given intravenously, subcutaneously, or intradermally. A booster dose is described for people aged 15 to 55 years at continued risk, particularly if 4 to 5 years have passed since a previous dose.
Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.
Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.
Related Product Categories
SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.